January 21, 2017 2:01 PM ET


Company Overview of Akebia Therapeutics, Inc.

Company Overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is vadadustat, an oral therapy which has completed a Phase II study for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients; and clinical product candidate is AKB-6899, a small molecule HIF-PH inhibitor to treat oncology and ophthalmology. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

245 First Street

Suite 1100

Cambridge, MA 02142

United States

Founded in 2007

63 Employees





Key Executives for Akebia Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 52
Total Annual Compensation: $757.5K
Chief Financial Officer, Senior Vice President and Treasurer
Age: 48
Total Annual Compensation: $467.7K
Chief Medical Officer and Senior Vice President
Age: 63
Total Annual Compensation: $573.3K
Compensation as of Fiscal Year 2015.

Akebia Therapeutics, Inc. Key Developments

Akebia Therapeutics Enters into Collaboration and License Agreement with Otsuka Pharmaceuticals

Akebia Therapeutics entered into a collaboration and license agreement with Otsuka Pharmaceuticals for vadadustat, a developing treatment for anemia associated with chronic kidney disease. Under the terms of the deal, which could be worth more than $1 billion, Akebia is expected to receive $265 million for the project's continued progress. The company announced both it and Otsuka will contribute equally to efforts to commercialize the drug, in addition with sharing all costs and revenue. Akebia is also eligible to receive further payments that could total $765 million. The drug, an oral hypoxia-inducible factor stabilizer, is intended to help the estimated 1.8 million people conflicted with anemia cause by chronic kidney disease, which could result in a patient's death if left untreated. The drug maker has also struck up similar agreements with Mitsubishi Tanabe Pharma for the drug's development in Asia and is continuing discussions to find a partner for the European Union region.

Akebia Therapeutics, Inc. - Special Call

To discuss collaboration and license agreement in the U.S. for vadadustat

Akebia Therapeutics, Inc. Appoints Scott A. Canute to Serve on Compensation Committee and Nominating and Corporate Governance Committee of the Board, Effective January 1, 2017

At a regular meeting of the Board held on December 8, 2016, the Board of Akebia Therapeutics, Inc. appointed Mr. Scott A. Canute to serve on the Compensation Committee and the Nominating and Corporate Governance Committee of the Board, effective as of January 1, 2017.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Akebia Therapeutics, Inc., please visit www.akebia.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.